Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Acute graft-versus-host disease
F Malard, E Holler, BM Sandmaier, H Huang… - Nature Reviews …, 2023 - nature.com
Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of …
Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity
after allogeneic stem-cell transplantation. Because of the small number of results from well …
after allogeneic stem-cell transplantation. Because of the small number of results from well …
Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis
Background In patients undergoing allogeneic hematopoietic stem-cell transplantation
(HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against …
(HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against …
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation …
A Burchert, G Bug, LV Fritz, J Finke… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT),
patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the …
patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the …
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two …
Background Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor
(CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical …
(CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical …
Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease
Background Acute graft-versus-host disease (GVHD) remains a major limitation of
allogeneic stem-cell transplantation; not all patients have a response to standard …
allogeneic stem-cell transplantation; not all patients have a response to standard …
Acute graft-versus-host disease—biologic process, prevention, and therapy
When T cells from a bone marrow donor begin to attack the host within 3 months after
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …
hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease …
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Acute graft-versus-host disease (aGVHD) of the lower gastrointestinal (GI) tract is a major
cause of morbidity and mortality in patients receiving allogeneic hematopoietic stem cell …
cause of morbidity and mortality in patients receiving allogeneic hematopoietic stem cell …
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
M Jagasia, MA Perales, MA Schroeder… - Blood, The Journal …, 2020 - ashpublications.org
Patients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after
allogeneic hematopoietic cell transplantation have poor prognosis, highlighting an unmet …
allogeneic hematopoietic cell transplantation have poor prognosis, highlighting an unmet …
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia …
Background The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic
leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric …
leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric …